Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Esperion Therapeutics, Inc.NASDAQ: ESPR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $8.99M fell 28.4% year over year, behind the -2.4% change in trailing-twelve-month research & development. Sequentially, it fell 35.5% from the prior quarter. Over 3 fiscal years it compounded at -26.2% a year.
Context
- Research & development amounted to 11.9% of revenue in FY2025, down 2.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -28.4% toward the trailing-twelve-month pace of -2.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 47.85M USD
- Year-over-year change
- +3.5%
- 4-year CAGR
- -18.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.85M | +3.5% |
| FY2024 | 2024-12-31 | 46.24M | -46.3% |
| FY2023 | 2023-12-31 | 86.11M | -27.6% |
| FY2022 | 2022-12-31 | 118.93M | +12.2% |
| FY2021 | 2021-12-31 | 105.98M | — |
Research & Development vs competitors
How ESPR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.4% is the 6th highest of 10, against a peer median of +12.8%.
- Research & development amounts to 10.6% of revenue for ESPR, versus a peer median of 31.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.7T USD | +25130615.4% | -33.8% | 2884018.5% | |
| LTM Mar 2026 | $228.65M USD | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $176.31M USD | +40.8% | +24.2% | — | |
| LTM Mar 2026 | $84.33M USD | +24.0% | +11.4% | 4593.1% | |
| LTM Mar 2026 | $61.4M USD | -16.9% | +5.2% | 7.4% | |
| LTM Mar 2026 | $49.1M USD | -30.6% | -34.1% | 7.3% | |
| LTM Mar 2026 | $44.28M USD | -2.4% | -26.2% | 10.6% | |
| LTM Mar 2026 | $37.44M USD | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $16.04M USD | -18.6% | -0.6% | 31.9% | |
| LTM Mar 2026 | CA$393K CAD | -3.9% | -41.5% | 0.0% | |
| Peer median (excluding ESPR) | — | +12.8% | -0.6% | 31.9% | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.45M | 75.48M | 116.33M | 332.31M | 403.14M |
| Cost of Revenue | 14.22M | 26.97M | 43.27M | 68.6M | 129.22M |
| Gross Profit | 64.23M | 48.51M | 73.07M | 263.71M | 273.91M |
| Gross Margin | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| Research & Development | 105.98M | 118.93M | 86.11M | 46.24M | 47.85M |
| Selling, General & Admin | 184.99M | 109.08M | 142.52M | 163.07M | 165.79M |
| Operating Expenses | 290.96M | 228.01M | 228.63M | 209.31M | 213.64M |
| Depreciation & Amortization | 612K | 500K | 164K | 63K | 105K |
| EBITDA | (222.14M) | (176.35M) | (150.11M) | 7.57M | 63.87M |
| EBITDA Margin | -283.2% | -233.7% | -129.0% | 2.3% | 15.8% |
| Operating Income | (226.73M) | (179.5M) | (155.56M) | 54.4M | 60.27M |
| Operating Margin | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.5M |
| Interest Expense | 46.35M | 56.81M | 58.98M | 59.25M | 84.6M |
| Other Income / Expenses | (42.38M) | (54.16M) | (53.69M) | (106.15M) | (81.11M) |
| Income Before Tax | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (20.84M) |
| Pre-Tax Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.84M |
| Net Income | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (22.68M) |
| Net Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (Basic) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| EPS (Diluted) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| Weighted Avg Shares | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
| Weighted Avg Shares (Diluted) | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.